The latest price target for Clover Health Investments (NASDAQ:CLOV) was reported by UBS on October 7, 2024. The analyst firm set a price target for $4.00 expecting CLOV to rise to within 12 months (a possible 18.69% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Clover Health Investments (NASDAQ:CLOV) was provided by UBS, and Clover Health Investments initiated their neutral rating.

The last upgrade for Clover Health Investments Corp happened on February 2, 2022 when Cowen & Co. raised their price target to $3. Cowen & Co. previously had an underperform for Clover Health Investments Corp.

The last downgrade for Clover Health Investments Corp happened on January 7, 2022 when Credit Suisse changed their price target from $9 to $3.5 for Clover Health Investments Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clover Health Investments, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clover Health Investments was filed on October 7, 2024 so you should expect the next rating to be made available sometime around October 7, 2025.

While ratings are subjective and will change, the latest Clover Health Investments (CLOV) rating was a initiated with a price target of $0.00 to $4.00. The current price Clover Health Investments (CLOV) is trading at is $3.37, which is within the analyst’s predicted range.